Clinical Trials Logo

Clinical Trial Summary

The RAINBOW study is a fully remote study focused on understanding and treating behavior problems in young children with tuberous sclerosis complex (TSC). The first goal is to enroll a group of 100 children with TSC between the ages of 3 and 6 years old, with and without problem behaviors, to learn about how best to measure behavioral challenges in TSC and how common these behaviors are during this age period. All families will get feedback from the clinical assessments collected. Eligible children who are experiencing behavior problems will be invited to enroll in a pilot clinical trial of internet-based Parent-Child Interaction Therapy (or PCIT), which is meant to help parents better manage their children's challenging behaviors. Adaptations to PCIT are incorporated to suit the needs of TSC children and families. Some participants will be randomly selected to receive the intervention immediately and others after a 6-month delay, but all families will receive the same intervention. Intervention sessions occur on a weekly basis for up to 20 weeks. Follow-up assessments, which include play interactions, parent interviews, and questionnaires occur about 3 and 6 months after the first visit. The delayed treatment group has an extra brief assessment about 12 months from the initial visit. This study will increase what is known about the types of behavior problems that come up during preschool age in TSC and how best to help children and families with TSC who are experiencing these problems.


Clinical Trial Description

The proposed study uses a telehealth approach to remotely assess and treat behavior problems in preschool-aged children with TSC. This study aims to 1) measure the prevalence and quality of externalizing behavior problems and their relation to family functioning in preschool-aged children with TSC; 2) examine the feasibility and acceptability of internet-based PCIT (I-PCIT) in children with TSC; 3) investigate the effects of I-PCIT on child and parent behavior in preschool-aged children with TSC and behavior problems; and 4) examine predictors of treatment response. For Aim 1, 100 children with TSC ages 3-6 years old will be enrolled. Developmental abilities and behavior problems will be assessed using norm-referenced parent report measures and video recordings of parent-child interactions. The prevalence of behavior problems in young children with TSC and relation to family functioning will be assessed. A subset of the children from Aim 1 who exhibit elevated externalizing behavior will be recruited for the pilot intervention, with a target sample size of 32. Children will be randomized to an immediate treatment or waitlist control group. Assessments will be performed at baseline (using Aim 1 data), mid-point (3 months later), and post-treatment (6 months later). Families randomized to the waitlist group will have a brief, additional post-treatment assessment 12 months post-baseline). Sessions occur on a weekly basis for up to 20 weeks. Preliminary efficacy will be examined by comparing trajectories from baseline to post-treatment between the immediate treatment and waitlist control groups. Data on feasibility, acceptability, and predictors of treatment response will be studied across all intervention participants. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06311474
Study type Interventional
Source University of California, Los Angeles
Contact Viviana Rodriguez
Phone 424-326-3118
Email vivianarodriguez@mednet.ucla.edu
Status Recruiting
Phase N/A
Start date August 1, 2022
Completion date July 31, 2025

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Recruiting NCT03422367 - JASPER Early Intervention for Tuberous Sclerosis N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Enrolling by invitation NCT03836300 - Parent-Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT02104011 - Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Phase 2
Recruiting NCT02461459 - Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Completed NCT01526356 - Topical Rapamycin to Erase Angiofibromas in TSC Phase 2
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Terminated NCT01092208 - Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Active, not recruiting NCT01954693 - A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Phase 2
Completed NCT03826628 - Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Phase 2/Phase 3
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT05286632 - KidneYou - Innovative Digital Therapy N/A
Withdrawn NCT04344626 - Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery N/A
Recruiting NCT05199402 - Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases